“Looks like they had solid results from their ph
Post# of 153778
(Total Views: 804)
Posted On: 11/24/2020 11:28:11 PM
“Looks like they had solid results from their phase 3 interim analysis.”
Yes, it appears SACCOVID is a direct competitor to leronlimab for the S/C population. Oncoimmune completed enrollment of this trial (270 patients) on September 24th, so full data should be available soon (published or PRed).
“Also looks like they only sold the COVID indication for $425 Million.”
Merck likely got to peek at this data (Oncoimmune is a private company) and liked what they saw before making an offer. They only paid $425 million upfront, but there is a clause for Oncoimmune investors to get a share of the profits from the COVID indication.
The drug is also safe per a comment from the CEO regarding an safety review by the IRB at 70 patients, “We have seen neither infusion reactions nor other drug-related adverse events associated with the trial in first 70 patients.“ But we’ll need to see full data to gauge true safety.
Let’s get the interim analysis back from 293 patients at 28 days and get an EUA. NP sees the window getting tighter for this opportunity and has impressively sped up trial enrollment.
Yes, it appears SACCOVID is a direct competitor to leronlimab for the S/C population. Oncoimmune completed enrollment of this trial (270 patients) on September 24th, so full data should be available soon (published or PRed).
“Also looks like they only sold the COVID indication for $425 Million.”
Merck likely got to peek at this data (Oncoimmune is a private company) and liked what they saw before making an offer. They only paid $425 million upfront, but there is a clause for Oncoimmune investors to get a share of the profits from the COVID indication.
The drug is also safe per a comment from the CEO regarding an safety review by the IRB at 70 patients, “We have seen neither infusion reactions nor other drug-related adverse events associated with the trial in first 70 patients.“ But we’ll need to see full data to gauge true safety.
Let’s get the interim analysis back from 293 patients at 28 days and get an EUA. NP sees the window getting tighter for this opportunity and has impressively sped up trial enrollment.
(1)
(0)